Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Dec 20, 2018
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares Oct 11, 2018
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares Oct 4, 2018
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures Oct 1, 2018
Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM Aug 29, 2018